Cardiff Oncology

🚨Phase 2 clinical trial data update🚨 Today, Cardiff Oncology announced positive initial data from CRDF-004, a randomized Phase 2 #clinicaltrial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line metastatic #colorectalcancer (mCRC). With 30 patients spanning 6 control arms, there was a 64% objective response rate in the onvansertib group at a 30mg dose versus 33% in the control group. “These data support our belief that onvansertib has potential to change the treatment paradigm for the entire first-line RAS-mutated mCRC #patient population of 50,000 new patients diagnosed in the U.S. annually,” said Mark Erlander, Ph.D., Cardiff Oncology CEO. We look forward to providing additional updates from our CRDF-004 trial in the first half of 2025. Learn more: https://ow.ly/j19g50Uob7S

Cardiff at San Antonio Breast Cancer Symposium! The Cardiff Oncology team had a fantastic time at #SABCS24. Dr. Sreeja Sreekumar, PhD and Dr. Maya Ridinger, PhD presented two posters, showcasing the potential of lead clinical asset onvansertib, in combination therapies for HR+ breast cancer. The posters highlighted preclinical findings demonstrating that onvansertib enhances the anti-tumor efficacy of trastuzumab deruxtecan or paclitaxel in endocrine therapy- and CDK4/6 inhibitor-resistant HR+/HER2- #breastcancer models. The team also shared mechanistic insights into the synergistic efficacy of onvansertib and paclitaxel. Congrats to everyone involved in these programs. If you missed us at the #SABCS event, both posters are available on our website: https://lnkd.in/eRAJqQsV #cancerresearch

Watch CEO Mark Erlander, Ph.D. sit down with BiotechTV to discuss our recent interim CRDF-004 Phase 2 data and what’s coming in 2025 for onvansertib.

We’re honored to see our Chief Scientific Officer, Dr. Tod Smeal, featured in Partnology’s Biotech Leader Spotlight Series! 🎉 Over the past 20 years of his career, Dr. Smeal has been at the forefront of #oncology innovation. His work, at major organizations like Pfizer, Eli Lilly, and Sugen, has contributed to the development of numerous first-in-human drugs and FDA-approved therapies. This extensive experience led him to becoming our CSO, where he focuses on advancing onvansertib which has the potential to transform treatment for KRAS-mutant metastatic #colorectalcancer. Thank you again, Partnology, for recognizing Dr. Smeal’s impact on #cancerresearch. 👇 Be sure to check out the full interview to learn more about Tod and his work in developing therapies that are turning the tide on #cancer.

Incredible momentum for Cardiff Oncology— we’re proud to announce today a successful round of financing resulting in $40 million in capital, with oversubscribed demand! We are grateful to our investors and underwriters for their support as we continue to accelerate the development of onvansertib in first-line RAS-mutated metastatic #colorectalcancer (mCRC). Be sure to follow us to learn more about our mission to bring life-changing cancer treatments to patients in need. Read more: https://lnkd.in/gdbKRFvi #financialupdate #biotechfunding #cancerresearch

This week, Cardiff Oncology’s Principal Scientist Sreeja Sreekumar, PhD and Director of R&D Maya Ridinger, PhD will be presenting two posters at the San Antonio Breast Cancer Symposium that highlight preclinical findings on onvansertib in combination therapies.   We hope to see you there! Learn more: https://www.sabcs.org/ #BreastCancer #Cancerresearch #SABCS24 #SABCS

New patent for use of onvansertib 📢 We’re pleased to share that Cardiff Oncology has been issued a patent from the USPTO for our method of using onvansertib in combination with bevacizumab (bev) for the treatment of KRAS mutated metastatic #colorectalcancer (mCRC) patients who have not received previous treatment with bev. This further strengthens our intellectual property portfolio for onvansertib and marks an important milestone in our commitment to advancing this innovative therapy for #cancer treatment. Learn more: https://ow.ly/vpvA50UahVX

Today, Cardiff Oncology shared several Q3 2024 clinical and business updates. Highlights include: ☑️ Our CRDF-004 trial for first-line treatment of RAS-mutated metastatic #colorectalcancer (mCRC) evaluating onvansertib in combination with chemotherapy and bevacizumab (bev) continues to enroll, and we anticipate the initial readout from the randomized CRDF-004 trial by the end of 2024. ☑️ Our clinical data demonstrating the safety and activity of onvansertib combined with FOLFIRI and bev in second-line KRAS-mutant mCRC was published in the Journal of Clinical Oncology, the flagship publication of the American Society of Clinical Oncology (ASCO). ☑️ A recent publication of preclinical data in the peer-reviewed journal, Cancers MDPI, shows that the combination of onvansertib and alpelisib more effectively targets tumor growth and induction of apoptosis in #breastcancer models resistant to endocrine therapy and CDK4/6 inhibitors. Read more: https://ow.ly/GPFY50U2CAv #CancerResearch #Oncology

It’s with great excitement that we announce the publication of our Phase 2 #clinicaltrial data in the American Society of Clinical Oncology (ASCO)’s Journal of Clinical Oncology. The combination of Cardiff Oncology’s lead molecule onvansertib with FOLFIRI and bevacizumab (bev) for second-line treatment of KRAS mutant metastatic #colorectalcancer (#mCRC) demonstrated positive results. Our clinical findings were supported by compelling translational research. Key highlights from the study include: -     A 77% objective response rate in bev-naïve patients, compared to just 10% in those previously exposed. -     A median progression-free survival of 14.9 months for bev-naïve patients, demonstrating significant clinical benefit -     New discovery that onvansertib exhibits antitumor activity in combination with bev through the inhibition of angiogenesis. 👉 Read the full press release here: https://lnkd.in/eq7Wr9tJ Congratulations to everyone involved! Daniel Ahn, Maya Ridinger, PhD, Timothy Cannon, Lawrence Mendelsohn, Jason Starr, Joleen Hubbard, Anup Kasi, 'Afsaneh Barzi', Errin Samuelsz, Anju Karki, PhD, Ramanand Arun Subramanian, PhD, Divora Yemane, Roy Kim, Chu-Chiao (Crystal) Wu, MS, PhD, Peter J P Croucher, Tod Smeal, Ph.D., Fairooz Kabbinavar M.D., FACP, and Heinz Josef Lenz.

Did you know that 1 in 8 women in the United States will be diagnosed with #breastcancer in her lifetime? October is #breastcancerawarenessmonth! At Cardiff Oncology, we are committed to advancing cancer care through innovative research and breakthrough treatments across a range of #cancer types. This month, we stand in solidarity with those impacted by breast cancer and support ongoing efforts to improve diagnosis, treatment, and survival outcomes. For more resources, please visit the National Breast Cancer Foundation, Inc.: https://lnkd.in/etpVpWV